Immunology Startup Merida Bio Unveils $121M and a Lead Program for Graves’ Disease

Merida Biosciences is developing antibody-like drugs designed to selectively eliminate disease-driving autoantibodies while sparing healthy components of the immune system. Graves disease, which stems from the immune system’s attack on the thyroid gland, is the startup’s lead disease target. The post Immunology Startup Merida Bio Unveils $121M and a Lead Program for Graves’ Disease appeared…

Read More

Bevey Miner, Consensus Cloud Solutions

Consensus is taking fax data, received by rural clinics, post acute, substance abuse clinics, home health et al, and helping them put it into their systems of records–which are in general not FHIR-enabled. They allow those facilities & services to receive referrals from acute care hospitals. By 2027 many of these standards are going to…

Read More